Hong Kong Jintz Medical Technology Co., Limited

Jintz Medical is a Hong Kong and Shenzhen-based medical technology company founded in 2020, operating at the intersection of medical devices, AI diagnostics, and healthcare data infrastructure. With a mission of "pioneering technology innovation, empowering smart healthcare," the company develops two core platform technologies: PPG-based non-invasive hemodynamic monitoring and UWB radar-based contactless biosensing.

What distinguishes JintzMed is its proprietary VeriPPG™ Data Validity Labeling Engineering—a quality control system that ensures AI-ready physiological data. This addresses a critical industry challenge: medical AI models trained on unvalidated data produce unreliable results. VeriPPG™ has demonstrated 12-17% accuracy improvement in LLM-based depression prediction through data quality control alone.

The company's flagship JM2020 HRV Analyzer holds NMPA Class II certification with national insurance reimbursement codes, and has been deployed across oncology, gastroenterology, psychiatry, and cardiology departments. JintzMed is also developing the CPHAS contactless predictive health alert system in partnership with UK-based Nine Health Group, selected into HKSTP's SPIN Incubation Program.

With strong strategic partnerships with leading hospitals, and a clear pipeline of 3+ devices, JintzMed is looking for strategic investors and collaboration partners. We are positioned to capture value from China's aging population and the shift toward accessible, AI-driven healthcare.